GSK Receives Offer For Thrombosis Brands/NDB Site
GlaxoSmithKline has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB), France site from Aspen Pharmacare. A period of exclusivity has been agreed with Aspen, and GSK will respond to the offer subject to consultation with employees and the relevant works councils.
The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra (fondaparinux) and Fraxiparine (nadroparine; excluding China, India and Pakistan) brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. The proposed transaction is aligned to GSKâs strategy of focusing on products with the most growth potential and the delivery of its pipeline.